@article{467bf22eb7da41f3b63305d1e8d69093,
title = "Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children",
abstract = "Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.",
author = "Catherine Liu and Arnold Bayer and Cosgrove, {Sara E.} and Daum, {Robert S.} and Fridkin, {Scott K.} and Gorwitz, {Rachel J.} and Kaplan, {Sheldon L.} and Karchmer, {Adolf W.} and Levine, {Donald P.} and Murray, {Barbara E.} and Rybak, {Michael J.} and Talan, {David A.} and Chambers, {Henry F.}",
note = "Funding Information: Potential conflicts of interest. H.F.C. has received honoraria and research grants and has served as a consultant to Cubist, Ortho-McNeil, Pfizer, Theravance, and Targanta. S. E. C. has received honoraria from Forest and RibX, has served as a consultant for Merck and has received research support from Astellas, Cubist and AdvanDx. R.D. has received research funding from Pfizer, Clorox, Sanofi Pasteur, Sage, and GeneOhm. S.L.K. has received grant funding from Pfizer, has served as MRSA Leadership Advisor to Pfizer, and is participating in a pediatric daptomycin study. A.W.K. has received honoraria and grants from Cubist Pharmaceuticals, Merck, Wyeth, and Pfizer and has served as a consultant for Cubist Pharmaceuticals, Theravance, Astellas, Pfizer, Merck, and Ortho-McNeil and has owned stock from Cubist Pharmaceutical, Pfizer, and Johnson and Johnson. D.P.L. has received research support from Cubist, Johnson & Johnson, and Theravance and has served as a speaker for Cubist. B.E.M. has served as a consultant and received research support from Johnson & Johnson, Astellas, Pfizer, Cubist, Theravance, Targanta, Sanofi-Aventis, Vicuron Pharmaceuticals, and Wyeth-Ayerst. M.R. has received grants and or has served as a consultant speaker for the Pfizer, Cubist, Theravance/Astellas, Targanta, and Johnson & Johnson. D.A.T. has served on the advisory board to Pfizer, Ortho-McNeil, Astellas, Schering-Plough, and Replidyne. All other authors: no conflicts.",
year = "2011",
month = feb,
day = "1",
doi = "10.1093/cid/ciq146",
language = "English (US)",
volume = "52",
pages = "e18--e55",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "3",
}